The ODYSSEY OUTCOMES trial evaluated alirocumab, a PCSK9 inhibitor, in 18,924 patients with recent acute coronary syndrome (ACS) who were already on high-intensity or maximum tolerated statin therapy. The gene discussed is PCSK9; the disease is acute coronary syndrome.